NASDAQ:TPST Tempest Therapeutics Q4 2024 Earnings Report $0.93 -0.01 (-1.56%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$0.88 -0.04 (-4.42%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Tempest Therapeutics EPS ResultsActual EPS-$4.03Consensus EPS -$3.12Beat/MissMissed by -$0.91One Year Ago EPSN/ATempest Therapeutics Revenue ResultsActual Revenue$0.49 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATempest Therapeutics Announcement DetailsQuarterQ4 2024Date3/27/2025TimeBefore Market OpensConference Call DateThursday, March 27, 2025Conference Call Time4:00PM ETUpcoming EarningsTempest Therapeutics' Q2 2026 earnings is estimated for Monday, August 10, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Tempest Therapeutics Earnings HeadlinesTempest Therapeutics: Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-TJuly 21, 2026 | finanznachrichten.deTempest Therapeutics Announces Strategic Partnership with Senlang to Advance TPST-4003 into First-in-Human Study in Autoimmune DiseasesJuly 21, 2026 | quiverquant.comQThe pact that ran the world and dollar just expiredIn 1974, a U.S.-Saudi deal tied oil sales exclusively to dollars, forcing nations worldwide to hold dollars and recycle profits into Treasuries. That agreement came up for renewal in June 2024 and quietly lapsed. Since then, Saudi Arabia signed a $7 billion currency swap with China, began settling some oil trades in yuan, and joined Beijing's mBridge payment network. Meanwhile, the 10-year yield is pushing toward 4.4percent on a $39 trillion debt load. Garrett Goggin, CFA and CMT, says gold miners still priced for sub-$2,000 gold could hold the real leverage as this shift plays out.July 26 at 1:00 AM | Golden Portfolio (Ad)Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-TJuly 21, 2026 | globenewswire.comTempest Therapeutics Announces Advancement of Lead In Vivo CAR-T Candidate TPST-4003 into Planned Autoimmune Disease TrialJuly 15, 2026 | quiverquant.comQTempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026July 15, 2026 | globenewswire.comSee More Tempest Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tempest Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tempest Therapeutics and other key companies, straight to your email. Email Address About Tempest TherapeuticsTempest Therapeutics (NASDAQ:TPST) is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies. The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells. Additional preclinical programs aim to block key kinases involved in immune suppression, thereby complementing existing checkpoint inhibitors. Tempest has initiated early‐phase clinical studies in North America and Europe, collaborating with academic and industry partners to evaluate safety, pharmacokinetics, and preliminary efficacy in patients with advanced malignancies. Founded in 2017 and headquartered in Cambridge, Massachusetts, Tempest Therapeutics was established to translate cutting‐edge metabolic and immunological insights into novel oncology treatments. The company’s leadership team combines expertise in drug discovery, clinical development, and regulatory strategy, with decades of experience at both emerging biotechnology firms and large pharmaceutical companies. Tempest is supported by leading life‐science investors and maintains research collaborations to expand its pipeline and accelerate the delivery of new therapies to patients worldwide.View Tempest Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/20- 07/24Telecom Earnings Reveal a Sector That Finally Looks HealthierAMD and Cerbras Create A New Blueprint For HardwareIntel Earnings Reveal Whether the Chip Selloff Created a BuyRTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?Broadcom May Be the Biggest Winner From Alphabet's EarningsDefense Earnings Show Readiness Now and Modernization Ahead Upcoming Earnings Nucor (7/27/2026)Cadence Design Systems (7/27/2026)Coca Cola Femsa (7/27/2026)Welltower (7/27/2026)Astrazeneca (7/27/2026)PACCAR (7/28/2026)Ford Motor (7/28/2026)Boeing (7/28/2026)Ecolab (7/28/2026)Rio Tinto (7/28/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
